BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

Phase 1 Active not recruiting 20 enrolled Memorial Sloan Kettering Cancer Center Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this phase I clinical trial is to test the safety of these CAR T cells in patients with myeloma. There are two parts of this study. Part 1 of the study consists of screening for BCMA, Lenalidomide assignment and cell collection. Part 2 of the study is treatment with modified CAR T cells.

Timeline

Start: 2017-02-27
Primary completion: 2027-02
Completion: 2027-02

Publications

Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, Devlin SM, Smith M, Shah GL, Halton E, Diamonte C, Scordo M, Sauter CS, Mead E, Santomasso BD, Palomba ML, Batlevi CW, Maloy MA, Giralt S, Smith E, Brentjens R, Park JH, Perales MA, Mailankody S. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020 Aug 11;4(15):3776-3787. doi: 10.1182/bloodadvances.2020002509.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EGFRt/BCMA-41BBz CAR T cell	Cell therapy	300000 cells/kg	—
Subject	EGFRt/BCMA-41BBz CAR T cell	Cell therapy	1e+06 cells/kg	—
Subject	EGFRt/BCMA-41BBz CAR T cell	Cell therapy	3e+06 cells/kg	—
Subject	EGFRt/BCMA-41BBz CAR T cell	Cell therapy	1e+07 cells/kg	—
Subject	Lenalidomide	Other / unclassified	10 mg	Oral
Background	Cyclophosphamide	Other / unclassified	300 mg/m2	Intravenous
Background	Cyclophosphamide	Other / unclassified	3000 mg/m2	Intravenous
Background	Fludarabine	Small molecule	30 mg/m2	—

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications